Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Usually resolve within hours
Camizestrant monotherapy has demonstrated reliable efficacy and safety as monotherapy for advanced HR+ breast cancer, 360 with ongoing SERENA-4 (NCT04711252) and SERENA-6 (NCT04964934) clinical trials evaluating its efficacy when combined with CDK4/6 inhibitors
Ready to Get Started
Age, genetics, and existing health status all affect conversion rates
10 mg Vial Reconstitution BAC water added 2 mL Concentration 5,000 mcg/mL 250 mcg dose volume 0.05 mL = 5 units 500 mcg dose volume 0.10 mL = 10 units Doses per vial at 250 mcg 40 BAC water added 3 mL Concentration 3,333 mcg/mL 250 mcg dose volume 0.075 mL = ~7.5 units 500 mcg dose volume 0.15 mL = 15 units Doses per vial at 250 mcg 40 Units shown are U-100 insulin syringe units (where 100 units = 1.0 mL)
